Moderna, Inc.

The stock is in a powerful multi-month uptrend and sits near its 52-week high after reclaiming the 200-day moving average by a wide margin. That setup favors momentum continuation, but the move has already retraced a large part of the prior bear market, so shareholders should watch for consolidation after the sharp run.

Street sentiment is cautious-to-neutral, with a Hold consensus and a $44.88 target that sits well below the current share price. Recent actions have been mixed but mostly steady: several firms raised targets in May and June, while ratings largely stayed in Hold territory, with only one fresh Outperform and one Underperform.

The next print arrives with a mixed track record: Moderna has beaten 5 of the last 7 quarters, but the most recent quarter missed by 61.1%. Estimates still point to negative EPS next year at -4.6894, so the market will focus on cash burn, margin trajectory, and whether revenue growth can keep improving from the current 2.602% pace.

Recent insider activity leans to net selling, led by Stephen Hoge’s June 15 sale of 53,336 shares. Most other filings are exempt award, vesting, or tax-related transactions, which are less informative than discretionary selling; the pattern does not show meaningful insider accumulation.

Profitability remains weak, but the balance sheet is still a strength. Gross margin is -69.9%, operating margin is -131.1%, and free cash flow was -$1.681 billion in 2025, while cash and equivalents of $5.799 billion exceeded total debt of $1.916 billion by $3.883 billion.

Moderna still screens as a high-risk, cash-rich biotech with a pipeline-heavy profile rather than a steady earnings compounder. Versus large-cap healthcare peers, the setup is more about optionality and execution than current profitability, and the valuation remains below the market’s growth expectations despite the recent rebound.